Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
NEW HAVEN, Conn., May 04, 2018 -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018, at 9:20 a.m. ET at the Intercontinental Boston Hotel, Boston, MA.
The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage its capabilities across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to build a platform of potent and specific complement factor D inhibitors for AP-mediated diseases. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases. More information is available at http://www.achillion.com.
Investors & Media: Glenn Schulman, PharmD, MPH Achillion Pharmaceuticals, Inc. Tel. (203) 752-5510 [email protected]
